A Phase II Open-Label Multi-center Trial of Isotoxic Hypofractionated Radiotherapy for NSCLC
Chunmei Liu, Qiang Lin, Huandi Zhou, Xiaohui Ge, Chaoxing Liu, Dongxue Gao, Yufeng Zhang & Xiaoying Xue · Journal of Pharmaceutical Research International · 2022
Background: The standard treatment for advanced unresectable non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy. However, many poor Karnofsky score or elderly patients cannot tolerate it due to heir serious side effects. For patients who cannot tolerate concurrent...
Open access
Research Article
10.9734/jpri/2022/v34i32A36102